Moderna (NASDAQ:MRNA) stock is jumping again. Shares are up 9% today, trading near $57 in the Tuesday afternoon session. That extends a remarkable 2026 run for the mRNA pioneer. The move pushes ...

Shares of Moderna (NASDAQ: MRNA) jumped during the COVID-19 pandemic, but when its COVID-19 vaccine revenue dried up, the stock slumped. However, the company has recently shown it ...

Key Points Interested in Moderna, Inc.? Here are five stocks we like better. Moderna shares rose nearly 20% after Science Day ...

Shares of Moderna MRNA rose nearly 13% on Friday after the company unveiled a long-term strategy to transform itself from a ...

Moderna remains a Sell as regulatory setbacks, notably the FDA's Refusal-to-File for mRNA-1010, highlight persistent execution and approval risks. The RTF for mRNA-1010 delays potential influenza ...

Cancer was a key focus, with programs targeting solid tumors, Lynch syndrome, melanoma, and non-small cell lung cancer.

The recent downturn follows Moderna’s announcement that its melanoma vaccine, mRNA-4157, showed promising results in a Phase 2b study, reducing the risk of recurrence or death by 49% when combined ...

Moderna currently has three marketed products in its portfolio — two COVID-19 vaccines (Spikevax and mNexspike) and an RSV vaccine (mResvia). The Zacks Consensus Estimate for overall product sales is ...

Moderna (MRNA) faces major commercial setbacks as mRNA vaccines underperform against traditional competitors in post-pandemic markets. RSV and flu mRNA vaccines struggle with lower durability, higher ...

Moderna announced Thursday it will receive up to $54.3 million from a global vaccine partnership to fund its ongoing research into a potential bird flu mRNA vaccine, helping to recover some of the ...